

JC20 Rec'd PCT/PTO 21 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2004/005829

Filed: Intl. Filing 22 APR 2004

1st Inventor: Makoto Kobayashi

For: Novel Method of Screening

Atty. Dkt. No. 3171 USOP

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT

P.O. Box 1450

Commissioner for Patents

Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached forms be returned in accordance with MPEP §609.


Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated: 10/21/05

(847) 383-3372

(847) 383-3391



Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	Based on PCT/JP2004/005829
Filing Date	Intl. Filing 22 APRIL 2004
First Named Inventor	Makoto Kobayashi
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3171 US0P

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A1	WO 00/09538	02/24/2000	Merck & Co., Inc.		
	A2	WO 97/22004	06/19/1997	Merck & Co., Inc.		
	A3	WO 02/068600 A2	09/06/2002	Arena Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	Based on 10/554234
		Filing Date	Intl. Filing 22 APRIL 2004
		First Named Inventor	Makoto Kobayashi
		Art Unit	tba
		Examiner Name	tba
Sheet 2	of 2	Attorney Docket Number	3171 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A4	T. CHRISTOPHE, et al., "The Synthetic Peptide Trp-Lys-Tyr-Met-Val-Met-NH ₂ Specifically Activates Neutrophils through FPRL1/Lipoxin.....", The Journal of Biological Chemistry, (2001), Vol. 276, No. 24, pp. 21585-21593	
	A5	S. FUKUSUMI, et al., "Characteristics and Distribution of Endogenous RFamide-related Peptide-1", Biochim Biophys Acta, (2001), Vol. 1540, No. 3, pp. 221-232.	
	A6	N. MINAMINO, et al., "Neuromedin C: A Rombesin-Like Peptide Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1984), Vol. 119, No. 1, pp. 14-20.	
	A7	P.M. MURPHY, et al., "A Structural Homologue of the N-Formyl Peptide Receptor", The Journal of Biological Chemistry, (1992), Vol. 267, No. 11, pp. 7637-7643.	
	A8	L. BAO, et al., "Mapping of Genes for the Human C5a Receptor (C5AR), Human FMLP Receptor (FPR), and Two FMLP Receptor Homologue Orphan Receptors (FPRH1, FPRH2) to Chromosome 19", Genomics (1992), Vol. 13, No. 2, pp. 437-440.	
	A9	A.C. Mahon, et al., "The Small Cardioactive Peptides A and B of Aplysia are Derived from a Common Precursor Molecule", Proc. Natl. Acad. Sci. USA, (1985), Vol. 82, No. 11, pp. 3925-3929	
	A10	P. M. CONN, et al., "A New Receptor for Growth Hormone-Release Peptide", Science, (1996), Vol. 273, No. 5277, p. 923	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.